Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14220262 | 1.00 | ADRB2 (0.57) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL22607306 | 1.00 | ADRB2 (0.57) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL10215349 | 0.86 | ADRB2 (0.54) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL1145899 | 0.81 | ADRB2 (0.54) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL112701 | 0.81 | PKM (0.61) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL14291852 | 0.81 | ADRB2 (0.62) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL19236388 | 0.81 | ADRB2 (0.62) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL4122824 | 0.80 | ADRB2 (0.71) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL14622394 | 0.80 | ADRB2 (0.54) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL2579612 | 0.79 | ADRB2 (0.50) | ADRB2ADRB1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0361910-A1 | Granular pharmaceutical formulations | RHONE POULENC RORER LIMITED (GB) | 1990-04-04 | — | — | EP | claimed |
| US-20120321565-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| CN-101108809-B | 1- (alkylaminoalkyl-pyrrolidine-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists | THERAVANCE INC | 2010-07-14 | — | — | CN | disclosed |
| US-7709497-B2 | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090318494-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| US-7592329-B2 | Crystalline complexes of fluticasone-2-furoate | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| EP-1444248-B1 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES - 17-CARBOXY-LACTONE SUBSTITUTED STEROIDS WITH AN ARYL-CARBOXYLIC ESTER IN POSITION 17.ALPHA | GLAXO GROUP LTD (GB) | 2008-04-30 | — | — | EP | disclosed |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| WO-2008017827-A2 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017824-A1 | BICYCLO [2. 2. 1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-14 | — | — | WO | disclosed |
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| CN-101108809-A | 1- (alkylaminoalkyl-pyrrolidine-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists | THERAVANCE INC (US) | 2008-01-23 | — | — | CN | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| CN-1805927-A | 1- (alkylaminoalkyl-pyrrolidine-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists | THERAVANCE INC (US) | 2006-07-19 | — | — | CN | disclosed |
| EP-0361910-A1 | Granular pharmaceutical formulations | RHONE POULENC RORER LIMITED (GB) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | ADRB2 310/4885ADRB1 155/4885CYP1A2 337/4885 |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | ADRB2 429/4885ADRB1 220/4885CYP1A2 131/4885 |
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | PDE4A, PDE4B, PDE3B | ADRB2 86/4885ADRB1 51/4885CYP1A2 168/4885 |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | ADRB2 50/4885ADRB1 29/4885CYP1A2 265/4885 |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | PDE4A, PDE4B, PDE3B | ADRB2 284/4885ADRB1 216/4885CYP1A2 578/4885 |
| US-20090318494-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | ADRB2 43/4885ADRB1 32/4885CYP1A2 198/4885 |
| US-20120321565-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | CYP17A1, HSD17B7, NR5A1 | ADRB2 74/4885ADRB1 48/4885CYP1A2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.